All In Biotech

Drug Trial Radar · NCT06450886

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

An Open-label, Multicenter Study to Evaluate the Long-term Safety and Efficacy of Ulviprubart (ABC008) in Subjects Who Have Completed a Trial of Ulviprubart for the Treatment of Inclusion Body Myositis

Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

270

Planned (sponsor's estimate)

Start

Oct 21, 2024

Primary completion

Jan 2029

Study completion Apr 2029

Sponsor

Lead sponsor
Abcuro, Inc.Industry
Sponsor type
Industry
First posted
Jun 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and: * Have completed the Part 2 (Multiple Ascending Dose \[MAD\]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR * Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.

Conditions

  • Inclusion Body Myositis (IBM)

Interventions

  • Ulviprubart (ABC008)Drug

    All eligible subjects, regardless of treatment assignment or dose level in their initial study, will be administered ulviprubart at a dose of 2.0 mg/kg via subcutaneous (SC) injection Q8W.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EndpointTime frame: From Baseline (Day 1) through study completion, an average of 156 weeks.]

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Neuromuscular Research Center

    Phoenix, Arizona

  • University of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center

    Irvine, California

  • Keck Hospital of USC

    Los Angeles, California

  • Yale School of Medicine

    New Haven, Connecticut

  • Neuromuscular Diagnostic Center - Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Womens Hospital

    Boston, Massachusetts

  • Hospital for Special Surgery

    New York, New York

  • Duke Neurological Disorders Clinic

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • UPMC Arthritis and Autoimmunity Center, Falk Clinic

    Pittsburgh, Pennsylvania

  • Austin Neuromuscular Center

    Austin, Texas

  • Texas Neurology

    Dallas, Texas

  • Nerve and Muscle Center of Texas

    Houston, Texas

  • Virginia Commonwealth University

    Henrico, Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Royal North Shore Hospital

    Saint Leonards, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Perron Institute for Neurological and Translational Science

    Nedlands, Washington, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.